Optimizing Use of Biological Agents in Ulcerative Colitis

Introduction

Case 1: What to Do When Conventional Treatment Fails?

Case 1: What to Do When Conventional Treatment Fails? (cont)

Safety of Ibuprofen in Patients With IBD

Case 1: What to Do When Conventional Treatment Fails? (cont)

Endoscopic Remission as Treatment Target

The Mayo Endoscopic Subscore

Impact of Mucosal Healing on the Course of Disease

Case 1: Next Steps

Toronto Guidelines for the Management of Moderate to Severe Active UC

Toronto Guidelines for the Management of Moderate to Severe Active UC (cont)

Toronto Guidelines for Management of Corticosteroid-Resistant/Dependent UC

Considerations for Biologic Treatment

Vedolizumab: Onset of Action in UC

Vedolizumab Real-World Effectiveness: Meta-Analysis

Considerations for Starting Biologic Therapy

Treating to Target and Monitoring Response

Strategies to Optimize Anti-TNF Therapy

Vedolizumab Long-Term Safety Outcomes

Long-Term Efficacy Outcomes With Biologics

Case 2: What to Do When First Anti-TNF Therapy Fails?

Case 2: What to Do When First Anti-TNF Therapy Fails? (cont)

Case 2: What to Do When First Anti-TNF Therapy Fails? (cont)

Algorithm for Management of Patients With Continued Inflammation Receiving Infliximab

Algorithm for Management of Patients With Secondary LOR to Biologic

Algorithm for Management of Patients With Secondary LOR to Biologic (cont)

Pharmacokinetics of Anti-TNF Agents

Using Biologic Monotherapy vs Combination

Conclusions

Abbreviations

Abbreviations (cont)